Choose your Region

Are you sure you want to proceed?

You will be leaving the Cook Medical website that you were viewing and going to a Cook Medical website for another region or country. Not all products are approved in all regulatory jurisdictions. The product information on these websites is intended only for licensed physicians and healthcare professionals.

Peripheral Intervention

Zilver Vena® Venous Self-Expanding Stent

Study suggests effective treatment of symptomatic iliofemoral venous outflow obstruction1

The study, “Twelve-month end point results from the evaluation of the Zilver Vena venous stent in the treatment of symptomatic iliofemoral venous outflow obstruction (VIVO clinical study),” has shown that Zilver Vena is a safe and effective treatment option for patients diagnosed with symptomatic iliofemoral venous outflow obstruction.1

The VIVO clinical trial was conducted between December 2013 and October 2016 and was published in the Journal of Vascular Surgery Venous and Lymphatic Disorders. The multicenter study enrolled 243 patients in the United States and Taiwan with symptomatic venous outflow obstruction of one iliofemoral venous segment. All participants received the Zilver Vena stent.1

“One in three Americans over the age of 45 has some kind of vein disease,”2 according to the American Venous Forum. With chronic venous disease affecting 25 million adults in the United States,3 accessible treatment is crucial to maintaining quality of life for these patients, including those experiencing iliofemoral venous outflow obstruction.

Chronic venous outflow obstruction commonly refers to long-term stenotic and occlusive disease of the central veins or to iliofemoral outflow obstruction. Severe and chronic obstruction of the iliac veins can result in life-altering symptoms including chronic pain, while treatment options like anticoagulant therapy are not one-size-fits-all approaches to treating venous conditions.

The VIVO clinical study results showed that “the 30-day freedom from major adverse events rate was 96.7%, greater than the literature-defined performance goal of 87%.”1 Similarly, “the 12-month primary quantitative patency rate was 89.9%, greater than the literature-defined performance goal of 76%.”1

“The primary safety end point was 30-day freedom from major adverse events,”1 and “the primary effectiveness end point was the 12-month rate of primary quantitative patency by venography as determined by the core laboratory.”1

The study also found that the Zilver Vena stent led to clinical symptom improvement compared with the baseline. The change in the Venous Clinical Severity Score (VCSS) from baseline was -3.0 at one month and and -4.2 at 12 months, respectively.1

  1. Hofmann L, Gagne P, Brown J, et al; VIVO study investigators. Twelve-month end point results from the evaluation of the Zilver Vena venous stent in the treatment of symptomatic iliofemoral venous outflow obstruction (VIVO clinical study). J Vasc Surg Venous Lymphat Disord. 2023;11(3):532–541.e4. doi: 10.1016/j.jvsv.2022.12.066.
  2. What is vein disease and lymphedema? American Venous Forum Web site. Accessed June 15, 2023.
  3. Eberhardt RT, Raffetto JD. Chronic venous insufficiency. Circulation. 2014;130(4):333–46.

Please see product risk information in the IFU at


Thank You for Your Interest in Cook Medical's Products

The product information on this website is intended only for physicians and healthcare professionals licensed in the European Union (except France), the United Kingdom, Switzerland, Norway, Iceland, Turkey, and Liechtenstein. If you are located in another global region, please click on the regional flag at the very top of the webpage and choose your region from the drop-down options.

If your region is not listed, visit our How to Order section for more information.

Information provided on this site is not intended to be professional medical advice. Product Instructions for Use (IFU) should be consulted before use of any product.